Generic Name and Formulations:
Hepatitis A vaccine, inactivated 720 ELISA Units (EL.U.) per 0.5mL (pediatric), or 1440 EL.U. per 1mL (adult); susp for IM inj; aluminum adsorbed; contains neomycin (trace); preservative-free.
Indications for HAVRIX:
Hepatitis A immunization.
Inject into deltoid, preferably at least 2 weeks before expected exposure. >18yrs: 1440 EL.U. once IM; give booster dose 6–12 months after initial course.
Inject IM preferably at least 2 weeks before expected exposure. <12months: not recommended. 12months–18yrs: 720 EL.U. once IM; give booster dose 6–12months after initial course.
Neomycin allergy. Previous hypersensitivity reaction to hepatitis A-containing vaccine.
Have epinephrine (1:1000) inj available. Fever. Bleeding disorders. Immunodeficiency (may have suboptimal response). If given with immune globulin, use separate syringe and different site. Latex allergy. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressives may reduce efficacy. Concomitant vaccines: see literature.
Inj site reactions, headache, fatigue, fever, malaise, anorexia, GI upset.
Single-dose vials—10; Single-dose prefilled Tip-Lok syringes—5 (without needles)
Clinical Pain Advisor Articles
- Opioids: Clinician Concern and Prescribing Practices
- Quantity of Opioids Prescribed Linked to Higher Patient-Reported Consumption
- Screening for Hyperglycemia Prior to Steroid Injections for Chronic Pain
- Ensuring Safety During Long-Term Opioid Therapy
- Drug Overdose Mortality Rates Rising in the United States
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Business Degree Increasingly Useful for Doctors
- Intervention by Pharmacists May Effectively Reduce Use of Inappropriate Medications in the Elderly
- Tips Provided for Budgeting in Medical Residency
- Give Thanks: The Role of Gratitude in Combating Burnout
- Persistent Back Pain Linked to Earlier Mortality in Older Women
- Cannabinoids May Be Effective on Experimental Pain Threshold and Tolerance, Not Intensity
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain